4//SEC Filing
Scheessele William John 4
Accession 0001818382-22-000201
CIK 0001818382other
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 4:15 PM ET
Size
5.4 KB
Accession
0001818382-22-000201
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Scheessele William John
Chief Commercial Officer
Transactions
- Award
Stock Options (right to buy)
2022-12-08+136,000→ 136,000 totalExercise: $3.07Exp: 2032-12-08→ Common Stock (136,000 underlying)
Footnotes (1)
- [F1]The first 25% of the option becomes exercisable on December 8, 2023, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2026.
Documents
Issuer
Humacyte, Inc.
CIK 0001818382
Entity typeother
Related Parties
1- filerCIK 0001879378
Filing Metadata
- Form type
- 4
- Filed
- Dec 11, 7:00 PM ET
- Accepted
- Dec 12, 4:15 PM ET
- Size
- 5.4 KB